On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...
This mouse model of ALS overexpresses wild-type human TARDBP (TDP-43) in postnatal neurons. Mice in this line, called TAR4, develop ALS-related phenotypes, including severe motor impairment, loss of ...
At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...
As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...
Missense mutations that derail SORL1 trafficking cause AD. Other variants shift AD risk in East Asians and Europeans. SORL1 dysfunction messes with endosomes in neurons, and with lysosomes in ...
This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...
Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...
Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...
Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...
A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...
On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...
For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback